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What do we know? 
 
 
• Clopidogrel is mainly indicated for the prevention of vascular ischaemic events 
in patients with symptomatic atherosclerosis, non-ST elevation acute coronary 
syndrome and as an adjuvant to reperfusion therapy for ST segment elevation 
myocardial infarction (MI) with aspirin. 
• Clopidogrel is metabolised by hepatic cytochrome P450 2C19 to an active 
thiol metabolite that is specific and irreversible inhibitor of platelet P2Y12 
ADP receptor and inhibits platelet aggregation. 
 
• Evidence suggests that some PPIs (mainly omeprazole) can inhibit CYP 




What this study adds? 
 
 
• This study shows the prevalence of co-administration of clopidogrel with 
any PPIs in a cohort of aged cared residents in Western Australia. 
 
• A clinically significant number of aged-care residents in this cohort were taking 
the combination of clopidogrel and a PPI with almost 50% of the residents on a 
combination of clopidogrel with omeprazole. 
• Given the potential interaction between clopidogrel and PPIs, it is necessary 
to review the co-administration of clopidogrel with PPIs (especially 
omeprazole and esomeprazole) to prevent an adverse outcome in this group 
of patients. 
Abstract 
Background:  Recent studies have suggested that proton pump inhibitors (PPIs) inhibit 
the antiplatelet activity of clopidogrel increasing the risk of major cardiovascular events 
in patients taking clopidogrel and PPIs together. 
Aim: This study aims to determine the prevalence of co-administration of clopidogrel 
and proton pump inhibitors (PPIs) amongst residents of aged-care facilities in Western 
Australia. 
Methods: One year prescription records of 791 aged-care residents were analysed for 
prevalence of co-prescribing of clopidogrel and PPIs, and aspirin with clopidogrel and 
PPIs. Prevalence of co-prescribing of clopidogrel, aspirin and PPI in diabetic patients 
and clopidogrel with various CYP2C19 inhibitors was also examined.  
Results: Of the 791 residents 60 were prescribed clopidogrel, 248 were on aspirin, and 
326 were prescribed a PPI. Among residents who were prescribed PPIs, 155 were 
prescribed omeprazole, 72 pantoprazole, 15 lansoprazole, 44 esomeprazole and 51 
rabeprazole. Eleven of these residents had taken more than one PPI during the study 
period. Thirty nine residents took a combination of clopidogrel and a PPI (any PPI) for 
a mean 203 days (SD 12). Thirteen residents were on the combination of aspirin and 
clopidogrel for a mean of 202 days (SD 111). Nine residents took the combination of 
clopidogrel, aspirin and a PPI (any PPI) for a mean of 173 days (SD 81). Only one 
patient on clopidogrel was receiving a CYP2C19 inhibitor in addition to a PPI.  
Conclusions: A clinically significant number of residents in this cohort were taking the 
combination of clopidogrel and a PPI, mainly omeprazole. Residents who were on the 
combination of clopidogrel and a PPI with or without aspirin were on these 
combinations for a significantly long duration which could increase the risk of adverse 
cardiovascular events.  
Keywords: Clopidogrel, proton pump inhibitors, interaction, acute coronary 
syndrome, cardiovascular disease 
Introduction 
  
Clopidogrel is mainly indicated for the prevention of vascular ischaemic events in 
patients with symptomatic atherosclerosis, non-ST elevation acute coronary syndrome 
(ACS) [with aspirin] and as an adjuvant to reperfusion therapy for ST segment elevation 
myocardial infarction (MI) [with aspirin] 1. Proton pump inhibitors (PPIs) are generally 
prescribed to patients taking aspirin and clopidogrel as a prophylactic measure to 
prevent GI tract bleeding.  Recent studies have suggested that PPIs inhibit the 
antiplatelet activity of clopidogrel. This increases the risk of major cardiovascular 
events in patients taking clopidogrel and PPIs together following an ACS 1-3. 
Clopidogrel is a prodrug activated in the liver to an active thiol metabolite that is 
specific and irreversible inhibitor of platelet P2Y12 ADP receptor and inhibits platelet 
aggregation 4. This bioactivation is mediated by hepatic cytochrome P450 isoenzymes, 
with cytochrome P450 2C19 (CYP2C19) and  cytochrome P450 3A4 (CYP3A4) 
playing major roles 3. The genes encoding CYP2C19 are polymorphic and patients with 
reduced function CYP2C19 allele have lower levels of active metabolite of clopidogrel. 
The carriers of this allele were twice as likely to die from MI or stroke, as compared 
with non-carriers and have a three times increase in risk of stent thrombosis due to 
diminished platelet inhibition relative to those without such polymorphisms 4-6. Proton 
pump inhibitors are also metabolized by CYP2C19 in varying degrees 7. Evidence 
suggests that some PPIs can inhibit CYP2C19 and hence inhibit the bioactivation of 
clopidogrel 2. The randomized, double blind OCLA (Omeprazole Clopidogrel Aspirin) 
study 2 showed that omeprazole significantly decreased clopidogrel inhibitory effect on 
platelet P2Y12 as assessed by the vasodilator-stimulated phosphoprotein (VASP). The 
finding of this  study was consistent with a previous observational study which showed 
that patients using PPIs with the combination of clopidogrel and aspirin had 
significantly higher VASP values than nonusers of PPIs 8.  VASP phosphorylation in 
human platelets correlates with platelet aggregation and there is direct link between 
VASP and major adverse cardiac events 9. 
A retrospective cohort study in patients taking clopidogrel with or without a PPI after 
hospitalization for ACS reported that use of clopidogrel with a PPI was associated with 
an increased risk of death or rehospitalisation for ACS compared with use of 
clopidogrel without a PPI 10. Approximately 60% of patients that took a PPI medication 
in this study were prescribed omeprazole. 
A population based nested case-control study in 13636 patients (734 cases and 2057 
controls) reported that in patients taking clopidogrel following an acute MI, concurrent 
use of PPI was associated with increased risk of reinfarction (OR 1.27, 95% CI 1.03-
1.57 3. Pantoprazole which does not inhibit CYP2C19 was shown to have no association 
with readmission for MI.  
In contrast to the reported negative omeprazole-clopidogrel drug interaction, a 
mechanistic study 7 conducted in 300 coronary artery disease (CAD) patients 
undergoing PCI indicated that intake of pantoprazole or esomeprazole was not 
associated with impaired response to clopidogrel as assessed by VASP assay and 
aggregometry. Similarly a pharmacokinetic study in healthy subjects showed that 
lansoprazole did not alter the antiplatelet activity of clopidogrel measured as inhibition 
of platelet aggregation (IPA) 11.  
However, CYP2C19 does not appear to be a major metabolic pathway for clopidogrel 
metabolism with evidence suggesting that CYP3A4 is a major contributor of 
clopidogrel active metabolite generation.   Lau et al reported that atorvastatin reduces 
platelet inhibition by clopidogrel due to competitive inhibition of CYP3A4 substrate in 
a dose dependant manner 12. CYP3A4 stimulators rifampin and St. John’s Wort 
enhanced platelet inhibition by clopidogrel, whereas agents that compete with 
clopidogrel for CYP3A4 (e.g. erythromycin) attenuated platelet inhibition.  
 
Methods 
The study was approved by the Curtin University Human Research Ethics Committee. 
We studied the prescription records of 791 aged-care residents for the prevalence of co-
prescribing of clopidogrel and PPIs, and aspirin with clopidogrel and PPIs. The data file 
consisted of 65259 records of drugs prescribed over the course of a year (from 02-01-
2007 to 31-12-2007). We also studied the prevalence of co-prescribing of clopidogrel 
with various CYP2C19 inhibitors. The prevalence of co-prescribing of aspirin, 
clopidogrel and PPIs in diabetic residents was also determined as diabetics are at high 
risk of cardiovascular disease and more likely to be on this combination. 
PPIs included in analysis were omeprazole, pantoprazole, lansoprazole, esomeprazole, 
and rabeprazole. The CYP2C19 inhibitors included were cimetidine, efavirenz, 
fluoxetine, fluvoxamine, indomethacin, ketoconazole, modafinil, oxcarbazepine, 
ticlopidine, topiramate and voriconazole. We classified residents as diabetic if they were 
on any of the following anti-diabetic drugs, namely, insulin, metformin, glibenclamide, 
gliclazide, glimepiride, glipizide, pioglitazone, rosiglitazone, acarbose, and ripaglinide 
at any time during the study period. 
The data file consisted of all prescribed medicines for the random sample of aged care 
residents provided by Webstercare during 2007. It consisted of following fields: 
residents’ date of birth, gender, drug name, dose, dispensed date, date of 
commencement and the last date of taking the drug. Each patient was assigned with a 
unique code number. A person-based analysis was performed. Each person having the 
various available combinations of drugs and the duration for which they had been on the 
combination therapy were determined. This was to ascertain that the patients used the 
combination of drugs concurrently and not at different periods. The number of days a 
patient was on a drug or combination of drugs was calculated by dividing quantity of 
drug dispensed by dose per day. 
The data file was provided as a Microsoft Excel® spreadsheet but was transferred into 
DBF format for statistical analysis.  SAS statistical software program was used to obtain 
tables of the mean, standard deviations and median number of days when the different 
combinations of drugs were taken.  The DOS-based CLIPPER database program was 
used to calculate drug frequencies and identify the dates when each type of drug was 
taken, and from that the number of days for each combination of drugs taken.  
Case reports in Australia on cardiovascular events due to the combination of clopidogrel 
and PPI; and aspirin, clopidogrel and PPI were also obtained from ADRAC (Adverse 
Drug Reactions Advisory Committee). 
Results  
The data file consisted of records of 791 selected aged-care residents with a mean age of 
90 years (SD 12.1). There were 585 female residents with a mean age of 91 years (SD 
11.1) and 206 male residents with a mean age of 87 years (SD 12.5) [Table1]. 
Of 791 residents 60 were prescribed clopidogrel, 248 were prescribed aspirin, and 326 
were prescribed PPI (any PPI) [Table 2]. Among residents who were on PPI, 155 were 
on omeprazole, 72 on pantoprazole, 15 on lansoprazole, 44 on esomeprazole and 51 on 
rabeprazole. Eleven of these residents had taken more than one PPI during the study 
period. 
Thirty nine residents were on the combination of clopidogrel and a PPI (any PPI) for 
mean 202.9 days (SD 11.5). Of the 39 people on clopidogrel and a PPI, 18 residents 
were on omeprazole, 9 on rabeprazole, 7 on esomeprazole, 6 on pantoprazole and 1 on 
lansoprazole [Table 3]. 
Thirteen residents were on combination of aspirin and clopidogrel for the mean of 202.3 
days (SD 111.1). Nine residents took the combination of clopidogrel, aspirin and a PPI 
(any PPI) for mean 203.1 days (SD 81). Among patients taking aspirin, clopidogrel and 
PPI, 6 were on omeprazole for mean 222.2days (SD 77) and 3 patients were on 
rabeprazole for mean 165 days (SD 90.6) [Table 4].  
The co-administration of clopidogrel with another CYP2C19 inhibitor was only 
observed in one resident who took a combination of fluoxetine and clopidogrel for 29 
days. Five diabetic patients were on the combination of clopidogrel and a PPI (any PPI) 
for the mean of 206.4 days (SD 105.8) with 3 residents on pantoprazole, 1 on 
omeprazole and 1 on esomeprazole [Table 5].  Only 1 diabetic resident in this cohort 
was taking combination of aspirin, clopidogrel and omeprazole for 151 days [Table 6]. 
One case report on adverse cardiovascular event was obtained from ADRAC regarding 
the combination of aspirin, clopidogrel and PPI.  The case was reported in December 
2008 and involved a 76 year old male patient who was on the combination of aspirin, 
clopidogrel and omeprazole. He suffered bradycardia and coronary artery occlusion 
reported as result of the drugs being ineffective.  
 
Discussion  
Clopidogrel is one of the highest selling drugs in the world.  In 2003, 1.3 million PBS 
prescriptions for clopidogrel were dispensed in Australia 13. Clopidogrel supply has 
increased rapidly in Australia since its introduction, from 1.2 to 9.0 defined daily doses 
(DDD)/1000 population/day.  The DDD/thousand population/day shows how many 
people, in every thousand patients, are taking the standard dose of a drug every day. 
Between 30% and 73% of clopidogrel supply was accounted for by people receiving 
cardiac stents 14. Proton pump inhibitors are also one of the most frequently prescribed 
classes of drug in the world with expenditure of approximately 14.3 billion US dollars 
globally in the year 2006 alone 15.  In Australia 4.42 million PBS prescriptions for 
esomeprazole and 3.88 million prescription for omeprazole were dispensed in the year 
2006-07 making them third and fourth most prescribed subsidised drugs in that year 
respectively 16. Recent guidelines from the American Heart Association, the American 
College of Gastroenterology, and the American College of Cardiology recommend a 
PPI for many patients receiving aspirin following a heart attack 17.  Clopidogrel and 
aspirin are often prescribed together for patients treated either medically or with 
percutaneous coronary intervention (PCI) following a heart attack. It is likely that 
millions of patients worldwide will take the combination of clopidogrel and a PPI. 
Considering the widespread use of these medications, it becomes important to further 
research the interaction between these drugs. 
A significant association was reported between clopidogrel and PPIs suggesting that 
their concomitant use may lead to attenuation of the benefits of clopidogrel leading to 
adverse cardiac outcomes 10. A randomized controlled trial showed that omeprazole 
significantly decreased clopidogrel inhibitory effect on platelet P2Y12 ADP receptor.  
Depending on the exposure to these drugs following a heart attack, it was estimated that 
5-15% of early readmissions for MI among patients taking clopidogrel could be the 
result of this drug interaction 3. Studies show that longer duration of treatment with 
clopidogrel plus PPI was associated with adverse outcomes 3, 10. Our study showed that 
residents, who were on combination of clopidogrel and PPI, with or without aspirin, 
were on these combinations for a significantly long duration (mean of 202 days a year). 
It is also important to assess if inhibition of clopidogrel action by PPIs is a drug effect 
or class effect. The reported negative effects of omeprazole on clopidogrel function was 
not seen in patients treated with pantoprazole, esomeprazole and lansoprazole 7, 11. 
However there was no study done to directly compare the effects of different PPIs on 
clopidogrel function. Evidence suggests that omeprazole is most likely to decreases 
anti-platelet activity of clopidogrel possibly due to inhibition of the CYP2C19 enzyme 2, 
3, 10. In our study 155 out of 326 (47%) patients who were taking PPI were on 
omeprazole. The only case report available from ADRAC involved omeprazole. 
Omeprazole was the first generic PPI, introduced in 2002, and still comprises majority 
of prescriptions for PPIs since its introduction 15. The adverse outcomes reported with 
omeprazole could be associated with its widespread use compared to other PPIs.  
Several studies have demonstrated that CYP2C19 gene polymorphism is associated 
with greater clopidogrel non-response and an increased risk of adverse cardiovascular 
events4, 6. Some studies showed that as many as 30% of people worldwide are born with 
this particular genetic variation 6. The way PPIs interfere with the conversion of 
clopidogrel to an active form may mimic this genetic variation that produces lower 
amounts of the enzyme. Individual with this polymorphism can be at an increased risk 
of thrombosis and this risk is further aggravated if they take a combination of 
clopidogrel with PPIs. Taking this genetic variation into account, Bonillo et al. 9 showed 
that adjusting the clopidogrel dose individually in patients according to their VASP 
index, before PCI, in daily clinical practice improved the clinical outcome after 
coronary stenting. This type of personalized medicine might also help in determining 
genetic status of individual patient, if one is a high responder or low responder to 
clopidogrel, and allow adjustment of treatment accordingly. 
The US Food and Drug Administration have released a communication about the safety 
review of potential interaction between clopidogrel and PPIs 18. The FDA highlighted 
the need for additional studies to evaluate the effectiveness of clopidogrel when used 
concurrently with PPIs. Until further information is available FDA issue the following 
advice 18:  
• Avoid using omeprazole and clopidogrel together and at any time of the day. 
• Avoid using other potent CYP 2C19 inhibitors, including esomeprazole, with 
clopidogrel. 
• FDA does not have enough evidence to preclude the use of other PPIs other than 
omeprazole and esomeprazole. 
• Patients taking clopidogrel should consult with their healthcare provider if they 
are currently taking or considering taking a PPI. 
• Patients who use clopidogrel and need a medication to reduce stomach acid can 
use antacids, ranitidine, famotidine, nizatidine but not cimetidine. 
A clinically significant number of aged-care residents in this cohort were taking the 
combination of clopidogrel and a PPI. Almost 50% of the residents who were on PPI 
were prescribed omeprazole. Residents on the combination of clopidogrel and a PPI, 
with or without aspirin, were on these combinations for a significantly long duration, 
which significantly increase the risk of adverse cardiac events. This drug interaction is 
now evident and it is necessary to review the co-administration of clopidogrel with PPIs 
(especially omeprazole and esomeprazole) in this group to prevent an adverse outcome. 
The clinical impact of these results must be assessed by further studies comparing 
cardiovascular outcomes for patients taking clopidogrel plus PPI versus clopidogrel 
without PPI, and comparing the impact of different PPIs on the effectiveness of 
clopidogrel. 
Acknowledgements 
We would like to thank Richard Parsons (Senior Lecturer in Statistics, School of 
Occupational Therapy and Social Work and School of Pharmacy, Curtin University of 
Technology) for statistical support and Gerard Stevens (Managing director, 
Webstercare) for the provision of the dispensing data.  




1. The Royal Australian College of General Practitioners, Australasian Society of 
Clinical and Experimental Pharmacologists and Toxicologists, Pharmaceutical 
Society of Australia. Australian Medicine Handbook. Adelaide: Australian 
Medicines Handbook Pty Ltd; 2008. 
2. Gilard M, Arnaud B, Cornily J, et al. Influence of omeprazole in antiplatelet 
action of clopidogrel associated with aspirin: the randomized, double-blind 
OCLA (Omeprazole Clopidogrel Aspirin) study. J Am Coll Cardiol 
2008;51(3):256-260. 
3. Juurlink D, Gomes T, Ko D, et al. A population-based study of the drug 
interaction between proton pump inhibitors and clopidogrel. CMAJ 
2009;180(7):e1-e7. 
4. Lepantalo A, Virtanen K, Resendiz J, et al. Antiplatelet effects of clopidogrel in 
patients with aspirin therapy undergoing percutaneous coronary interventions- 
limited inhibition of the P2Y12 receptor. Thromb Res 2009; 124: 193-8. 
5. Fontana P, Senouf D, Mach F. Biological effect of increased maintenance dose 
of clopidogrel in cardiovascular outpatients and influence of cytochrome P450 
2C19*2 allele on clopidogrel responsiveness. Thromb Res 2008;121:463-468. 
6. Mega J, Close S, Wiviott S, et al. Cytochrome P-450 polymorphisms and 
response to clopidogrel. N Engl J Med 2009;360(4):354-62. 
7. Siller-Matula J, Spiel A, Lang I, Kreiner G, Christ G, Jilma B. Effects of 
pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 
2009;157:148.e1-5. 
8. Gilard M, Arnaud B, Le Calvez G, Abgrall J, Boschat J. Influence of 
omeprazole on the antiplatelet action of clopidogrel associated to aspirin. J 
Thromb Haemost 2006;4:2508-2509. 
9. Bonello L, Camoin-Jau L, Arques S, et al. Adjusted clopidogrel loading doses 
according to Vasodilator-Stimulated Phosphoprotein Phosphorylation Index 
decrease rate of major adverse cardiovascular events in patients with clopidogrel 
resistance. J Am Coll Cardiol 2008;51:1404-11. 
10. Ho M, Maddox T, Wang L, et al. Risk of adverse outcomes associated with 
concomitant use of clopidogrel and proton pump inhibitors following acute 
coronary syndrome. JAMA 2009;301(3):937-944. 
11. Small D, Farid N, Payne C, et al. Effects of proton pump inhibitor lansoprazole 
on the pharmacokinetic and pharmacodyanamics of prasugrel and clopidogrel. J 
Clin Pharmcol 2008;48:475-484. 
12. Lau W, Waskell L, Watkins P, et al. Atorvastatin reduces the ability of 
clopidogrel to inhibit platelet aggregation: A new drug–drug interaction. 
Circulation 2003;107:32-37. 
13. ADRAC. Clopidogrel - haemorrhage and haematological disorders. Australian 
Adverse Drugs Reaction Bulletin 2004;23(4):14-15. 
14. Ostini R, Mackson J, Williamson M. Why is the use of clopidogrel increasing 
rapidly in Australia? An exploration of geographical location, age, sex and 
cardiac stenting rates as possible influences on clopidogrel use. 
Pharmacoepidemiology and Drug Safety 2008;17:1077-1090. 
15. Forgacs I, Loganayagam A. Overprescribing proton pump inhibitors. BMJ 
2008;336:2-3. 
16. Drug Utilisation Sub-Committee (DUSC) Database.  Top 10 drugs. Aust Pres 
2007;30(6): 142. 
17. Bhatt D, Scheiman J, Abraham N, et al. ACCF/ACG/AHA 2008 expert 
consensus document on reducing the gastrointestinal risks of antiplatelet therapy 
and NSAID use: a report of the American College of Cardiology Foundation 
Task Force on clinical expert consensus documents. Circulation 2008;118:1894-
1909. 
18. US Food and Drug Administration. Early communication about an ongoing 
safety review of clopidogrel bisulphate (marketed as Plavix) and omeprazole 





Table 1. Residents’ demographics 





Total 791 90.3 12.1 
Female 585 91.1 11.1 
Male 206 88.2 12.5 
 
Table 2. Number of residents on various drugs 
Drugs No. of residents  (%) 
Clopidogrel 60 7.6 
Aspirin 248 31.4 
PPI (any PPI) 326 41.2 
Omeprazole 155 19.6 
Pantoprazole 72 9.1 
Lansoprazole 15 1.9 
Esomeprazole 44 5.6 
Rabeprazole 51 6.4 
 
Table 3. Combination of clopidogrel with PPIs 
Drugs No. of residents (n) Mean no. of days SD 
Clopidogrel with    
PPI(any PPI) 39 202.9 11.5 
Omeprazole  18 182.1 137.3 
Pantoprazole  6 185.3 88.4 
Lansoprazole  1 62.0 - 
Esomeprazole  7 283.5 41.2 
Rabeprazole  9 172.6 103.4 
 
Table 4. Combination of clopidogrel and aspirin with PPIs. 
Drugs No. of patients Mean no. of days SD 
Clopidogrel and aspirin 13 202.3 111.1 
Clopidogrel and aspirin 
with 
   
PPI(any PPI) 9 203.1 81.0 
Omeprazole  6 222.2 76.9 
Rabeprazole  3 165.0 90.6 
 
Table 5.Combination of clopidogrel and PPI by diabetes status of residents 
 
Diabetic status Drugs No. of residents Mean no. 
of days 
SD 
Non-diabetic Clopidogrel with 
PPI(any PPI) 34 202.3 113.8 
Omeprazole  17 184.9 130.6 
Pantoprazole  3 177.6 78.7 
Lansoprazole  1 62.0 - 
Esomeprazole  6 277.6 41.8 
Rabeprazole  9 172.6 103.4 
    
Diabetic Clopidogrel with 
PPI(any PPI) 5 206.4 105.8 
Omeprazole  1 134.0 - 
Pantoprazole  3 193.0 114.8 
Lansoprazole  0 - - 
Esomeprazole  1 319.0 - 
Rabeprazole  0 - - 
Table 6. Combination of clopidogrel and aspirin with PPI by diabetes status 
of residents 





Non-diabetic Clopidogrel and aspirin with 
PPI (any PPI) 8 209.6 84.1 
Omeprazole  5 236.4 76.7 
Rabeprazole  3 165.0 90.6 
    
Diabetic Clopidogrel and aspirin with 
PPI (omeprazole) 1 151.0 - 
 
